A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
Saber Soltani, Amir Mohammad Zakeri, Mohammad Reza Karimi, Sara Akhavan Rezayat, Fateme Zomorodi Anbaji, Alireza Tabibzadeh, Parastoo Yousefi, Armin Zakeri, Ali Jafarpour, Mehdi Norouzi, Yousef Erfani, Vahdat Poortahmasebi
Journal of Pharmaceutical Research International · pp. 13–25 · Published 18 May 2020
10.9734/jpri/2020/v32i730455Abstract
Background: In December 2019, the pneumonia outbreak reported in Wuhan, Hubei Province, China. WHO introduced a novel coronavirus and the virus named Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) in January 2020. There are not any specific antiviral agents for coronavirus disease 19 (COVID‐19). Objective: Our review aimed to discuss treatment options and the efficacy of currently prescribed drugs and supportive care in COVID‐19 patients. Study Design: A literature review of the articles in the Web of Science, PubMed, Scopus and EMBASE conducted. Results: Lopinavir/ritonavir combination was the most frequently used drug, followed by Arbidol and Oseltamivir and Methylprednisolone. Lopinavir/Ritonavir outcome showed the fever and respiratory infection improve in day two and day eight, respectively. Also, negative PCR of SARS‐CoV‐2 in days six and 7day was seen and finally these patients discharged in 10 days. Conclusions: Lopinavir/Ritonavir was the most improving administrated antiviral combination, which might be a good option for COVID-19 due to its availability. Although supportive care such as O2 supplementary and IV fluid therapy has improved outcomes. There are not evidence for suggesting a new treatment or a new drug, which mean the necessity of further investigations for drug research in a clinical trial for a conclusion about the optimum treatment.
Cited by 7
Department of Biochemistry, Health Science Institute, Ahi Evran Üniversitesi, Kirsehir, Türkiye, Khalid Z. Khalaf, Muhammad H. J. Alajeely · Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition · 2024
Azadeh Laali, Alireza Tabibzadeh, Maryam Esghaei · Advanced Biomedical Research · 2020
Saber Soltani, Mehrdokht Sadrkhanloo, Goli Siri · Jundishapur Journal of Microbiology · 2023
Parastoo Hosseini, Shervin Afzali, Mohammadreza Karimi · Reviews in Medical Microbiology · 2021
Nasim Kiaie, Seyedeh Parvin Mousavi Ghanavati, Sara Sadat Miremadi · International Journal of Stem Cells · 2021
Biswa Mohan Sahoo, Subrat Kumar Bhattamisra, Sarita Das · Current Drug Discovery Technologies · 2022
Zahra Siavashpour, Neda Goharpey, Mosayyeb Mobasheri · Critical Reviews in Oncology/Hematology · 2021
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Using Ultraviolet A to Check Inanimate Objects for Thorough Cleanliness during COVID-19 Pandemic — shares topic coverage
- The Evaluation of Biochemical Parameters in Positive COVID-19 RealTime PCR Patients: A Retrospective Study — shares topic coverage
- Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19) — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
7
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.